Hermes Garban
Research Subjects
Research Interests
Hermes Garban has a total of 138 co-authors. Here are the top co-authors by number of shared publications:
Benjamin Bonavida
5 shared publications- Benjamin Bonavida
Department of Microbiology, Immunology & Molecular Genetics, David Geffen School of Medicine, Jonsson Comprehensive Cancer Center, University of California, Los Angeles, CA 90095, USA
5 shared publications - Mario I. Vega
Molecular Signal Pathway in Cancer Laboratory, UIMEO, Oncology Hospital, Siglo XXI National Medical Center, IMSS, México City 06720, Mexico
5 shared publications Sara Huerta-Yepez
Department of Microbiology, Immunology, and Molecular Genetics, Jonsson Comprehensive Cancer Center, University of California-Los Angeles, 10833 Le Conte Ave., Los Angeles, CA 90095-1747, USA
5 shared publicationsJacob Rajfer
Departments of Urology, UCLA School of Medicine, Los Angeles, California 90509 5 Research and Education Institute, Harbor-UCLA Medical Center, Torrance, California 90502
4 shared publications- Antoni Ribas
Department of Medicine, Division of Hematology and Oncology, University of California, Los Angeles, Los Angeles, USA
3 shared publications
Latest Publications
- Open Access
- 5 November 2021
- Published by American Society of Hematology in Blood
- Vol. 138 (Supplement) , 1192
VIP152, a Selective CDK9 Inhibitor, Induces Complete Regression in a High-Grade B-Cell Lymphoma (HGBL) Model and Depletion of Short-Lived Oncogenic Driver Transcripts, MYC and MCL1, with a Once Weekly Schedule
Background: High-grade B-cell lymphoma (HGBL), previously known as double-hit lymphoma (DHL), is an aggressive type of B-cell non-Hodgkin lymphoma characterized by rearrangements in MYC and BCL2 or BCL6, which drive oncogenic transcription and anti-apoptotic signaling, respectively, and is refractory to standard of care chemotherapy. VIP152 is a well-tolerated and clinically active CDK9 inhibitor leading to complete metabolic remissions in 2/7 HGBL patients treated with once weekly (QW) 30 mg intravenous administration (Lücking et al. J Med Chem 2021; Moreno et al. JCO 2021 (abstr 7538)). Herein, we demonstrate that once weekly inhibition of CDK9 provides an "oncogenic shock"-like (Jain et al. Science 2002) disruption of transcription of MYC and other short half-life mRNA gene transcripts, which provides durable control of oncogenic protein levels without continuous dosing, resulting in apoptosis and antitumor efficacy. Methods: To understand the mechanism of antitumor efficacy, an evaluation of the pharmacodynamic (PD) extent and duration of CDK9 pathway inhibition was performed in vitro using HGBL cell lines treated with 250 nM VIP152 4 hours (h) pulse and washout time course. PD biomarkers include pSer2 and total RNA Pol II, MYC, MCL1, PCNA and cleaved PARP measured by western blot and RNAseq for transcriptome analysis with confirmation of key short half-life gene transcripts MYC, MCL1 and PCNA by qPCR. The efficacy of VIP152 QW regimen and control following a 2-week regrowth period was evaluated in an SU-DHL-10 in vivo xenograft mouse model. Longitudinal levels of short-lived transcripts compared with the transcriptome were evaluated by RNAseq of whole blood collections predose and postdose on Cycle 1 Day1, Day 8 and Day 15 from 7 HGBL patients treated with 30mg VIP152 QW. Pharmacokinetic /pharmacodynamic (PK/PD) modeling was performed to characterize concentration-effect relationships in 7 HGBL patients for VIP152 on MYC, MCL1 and PCNA mRNA. Results: In vitro treatment with VIP152 shows ≤12h inhibition of p-Ser2 RNAPol II, the direct substrate of CDK9. Stalling of transcriptional activity by RNAPol II was confirmed with a 6-hour depletion of MYC, MCL1 and PCNA mRNA, as measured by qPCR. Transcriptome analysis demonstrates transient control of gene expression by VIP152 is selective for a subset of genes with a short mRNA half-life. Furthermore, ≤16h of depletion of MYC, MCL1 and PCNA protein confirms that a short pulse of VIP152 treatment is sufficient for durable clearance of oncogenic drivers when mRNA levels are transiently downregulated. VIP152-mediated oncogenic shock is characterized by protein depletion rendering cells susceptible to apoptosis with cPARP peaking at 4h after washout. To assess the relevance of MYC depletion, VIP152 was evaluated in a MYC fusion+ DLBCL in vivo model (SU-DHL-10). Dose dependent regressions are achieved following 3 doses of VIP152 with 10- and 15-mg/kg QW regimens providing 81% and 98% tumor growth inhibition, respectively, compared with vehicle control. After 2 weeks regrowth of the 15 mg/kg group, retreatment with 2 doses of VIP152 provides 82% tumor volume reduction demonstrating the QW schedule is sufficient to suppress outgrowth (Figure 1). In HGBL patients (n=7), biomarker modulation is transient with the average maximum postdose depletion of MYC, MCL1 and PCNA mRNA being 94% at 1.4h, 70% at 2.3h and 86% at 4.0h relative to baseline, respectively. Transcriptome analysis confirms that the mechanism of action elucidated from preclinical models translates to patients wherein short half-life transcripts of key oncogenic drivers such as MYC, MCL1 and PCNA are selectively controlled after each of the first 3 QW 30 mg doses of VIP152. Unbound VIP152 IC 50 for MYC, MCL1 and PCNA is 25.4, 30.7, and 20.5 nM, respectively. These are comparable to in vitro DLBCL cell line VIP152 unbound IC 50 of 47 nM. Conclusions: CDK9 inhibition with VIP152 selectively depletes short half-life transcripts including MYC, a known driver of HGBL. Clearance of MYC, MCL1 and PCNA protein demonstrates VIP152 control of multiple parallel oncogenic pathways in the clinic and in HGBL preclinical models. Dose-dependent regression and tumor-outgrowth control demonstrates that VIP152 QW treatment can drive antitumor efficacy. VIP152 is currently being evaluated in HGBL patients and other indications in the clinic (ClinicalTrials.gov Identifiers: NCT02635672 and NCT04978779).
- 5 November 2021
- Published by American Society of Hematology in Blood
- Vol. 138 (Supplement) , 1192
Open AccessVIP152, a Selective CDK9 Inhibitor, Induces Complete Regression in a High-Grade B-Cell Lymphoma (HGBL) Model and Depletion of Short-Lived Oncogenic Driver Transcripts, MYC and MCL1, with a Once Weekly Schedule
Background: High-grade B-cell lymphoma (HGBL), previously known as double-hit lymphoma (DHL), is an aggressive type of B-cell non-Hodgkin lymphoma characterized by rearrangements in MYC and BCL2 or BCL6, which drive oncogenic transcription and anti-apoptotic signaling, respectively, and is refractory to standard of care chemotherapy. VIP152 is a well-tolerated and clinically active CDK9 inhibitor leading to complete metabolic remissions in 2/7 HGBL patients treated with once weekly (QW) 30 mg intravenous administration (Lücking et al. J Med Chem 2021; Moreno et al. JCO 2021 (abstr 7538)). Herein, we demonstrate that once weekly inhibition of CDK9 provides an "oncogenic shock"-like (Jain et al. Science 2002) disruption of transcription of MYC and other short half-life mRNA gene transcripts, which provides durable control of oncogenic protein levels without continuous dosing, resulting in apoptosis and antitumor efficacy. Methods: To understand the mechanism of antitumor efficacy, an evaluation of the pharmacodynamic (PD) extent and duration of CDK9 pathway inhibition was performed in vitro using HGBL cell lines treated with 250 nM VIP152 4 hours (h) pulse and washout time course. PD biomarkers include pSer2 and total RNA Pol II, MYC, MCL1, PCNA and cleaved PARP measured by western blot and RNAseq for transcriptome analysis with confirmation of key short half-life gene transcripts MYC, MCL1 and PCNA by qPCR. The efficacy of VIP152 QW regimen and control following a 2-week regrowth period was evaluated in an SU-DHL-10 in vivo xenograft mouse model. Longitudinal levels of short-lived transcripts compared with the transcriptome were evaluated by RNAseq of whole blood collections predose and postdose on Cycle 1 Day1, Day 8 and Day 15 from 7 HGBL patients treated with 30mg VIP152 QW. Pharmacokinetic /pharmacodynamic (PK/PD) modeling was performed to characterize concentration-effect relationships in 7 HGBL patients for VIP152 on MYC, MCL1 and PCNA mRNA. Results: In vitro treatment with VIP152 shows ≤12h inhibition of p-Ser2 RNAPol II, the direct substrate of CDK9. Stalling of transcriptional activity by RNAPol II was confirmed with a 6-hour depletion of MYC, MCL1 and PCNA mRNA, as measured by qPCR. Transcriptome analysis demonstrates transient control of gene expression by VIP152 is selective for a subset of genes with a short mRNA half-life. Furthermore, ≤16h of depletion of MYC, MCL1 and PCNA protein confirms that a short pulse of VIP152 treatment is sufficient for durable clearance of oncogenic drivers when mRNA levels are transiently downregulated. VIP152-mediated oncogenic shock is characterized by protein depletion rendering cells susceptible to apoptosis with cPARP peaking at 4h after washout. To assess the relevance of MYC depletion, VIP152 was evaluated in a MYC fusion+ DLBCL in vivo model (SU-DHL-10). Dose dependent regressions are achieved following 3 doses of VIP152 with 10- and 15-mg/kg QW regimens providing 81% and 98% tumor growth inhibition, respectively, compared with vehicle control. After 2 weeks regrowth of the 15 mg/kg group, retreatment with 2 doses of VIP152 provides 82% tumor volume reduction demonstrating the QW schedule is sufficient to suppress outgrowth (Figure 1). In HGBL patients (n=7), biomarker modulation is transient with the average maximum postdose depletion of MYC, MCL1 and PCNA mRNA being 94% at 1.4h, 70% at 2.3h and 86% at 4.0h relative to baseline, respectively. Transcriptome analysis confirms that the mechanism of action elucidated from preclinical models translates to patients wherein short half-life transcripts of key oncogenic drivers such as MYC, MCL1 and PCNA are selectively controlled after each of the first 3 QW 30 mg doses of VIP152. Unbound VIP152 IC 50 for MYC, MCL1 and PCNA is 25.4, 30.7, and 20.5 nM, respectively. These are comparable to in vitro DLBCL cell line VIP152 unbound IC 50 of 47 nM. Conclusions: CDK9 inhibition with VIP152 selectively depletes short half-life transcripts including MYC, a known driver of HGBL. Clearance of MYC, MCL1 and PCNA protein demonstrates VIP152 control of multiple parallel oncogenic pathways in the clinic and in HGBL preclinical models. Dose-dependent regression and tumor-outgrowth control demonstrates that VIP152 QW treatment can drive antitumor efficacy. VIP152 is currently being evaluated in HGBL patients and other indications in the clinic (ClinicalTrials.gov Identifiers: NCT02635672 and NCT04978779).
- 15 April 2012
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 72 (8_Suppleme) , 3491
Abstract 3491: Development of a new approach to kill non-small cell lung cancer cells with resistance to standard chemotherapy using parthenolide analogues
Lung cancer is the leading cause of cancer death in men and women worldwide. The poor prognosis of advanced non-small cell lung cancer (NSCLC) is due, in part, to emergence of tumor resistance to chemotherapy. Recent data indicate that human tumors including NSCLC contain a small subset of cancer stem/ progenitor cells (CSC) responsible for drug resistance and tumor maintenance. If such minute subsets of CSC drive tumor formation and drug resistance, therapies targeting the bulk tumor mass but not CSC will fail. We now confirm identification of subpopulations of chemotherapy-resistant human NSCLC cells with enrichment for CSC biomarkers and exhibiting significant CSC activity. We identified CD133+/ALDH+ tumor stem/progenitor cells from human lung cancer cells in vitro using established Aldefluor assays in combination with labeled anti-CD133 antibodies. Estrogen, a known risk factor for lung cancer progression, stimulated a modest increase in the numbers of CSC. In contrast to control CD133-/ALDH- tumor cell subsets, CSC subpopulations grew as tumor spheres and maintained self-renewal capacity in vitro and exhibited a greater tumorigenic capability than non-CSC subsets in vivo, properties indicative of CSC. Furthermore, resistance of CSC-like cells to cisplatin (a standard chemotherapy for NSCLC treatment) was fully reversed by treatment with parthenolide (PTL), a naturally-occurring sesquiterpene lactone compound with strong antitumor activity in leukemia and prostate cancer while sparing normal cells. The antitumor effect of PTL appears due to its action as a potent inhibitor of nuclear factor-βB (NF-κB) which is markedly activated by chemotherapy. To target CSC and suppress tumor progression, we synthesized and tested novel analogs of PTL with improved antitumor properties and aqueous solubility. PTL analogs inhibit proliferation of H157 NSCLC cells using both bulk cell preparations and CSC-subpopulations, with effects significantly different from control at PCitation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 3491. doi:1538-7445.AM2012-3491
- 15 April 2012
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 72 (8_Suppleme) , 3491
Abstract 3491: Development of a new approach to kill non-small cell lung cancer cells with resistance to standard chemotherapy using parthenolide analogues
Lung cancer is the leading cause of cancer death in men and women worldwide. The poor prognosis of advanced non-small cell lung cancer (NSCLC) is due, in part, to emergence of tumor resistance to chemotherapy. Recent data indicate that human tumors including NSCLC contain a small subset of cancer stem/ progenitor cells (CSC) responsible for drug resistance and tumor maintenance. If such minute subsets of CSC drive tumor formation and drug resistance, therapies targeting the bulk tumor mass but not CSC will fail. We now confirm identification of subpopulations of chemotherapy-resistant human NSCLC cells with enrichment for CSC biomarkers and exhibiting significant CSC activity. We identified CD133+/ALDH+ tumor stem/progenitor cells from human lung cancer cells in vitro using established Aldefluor assays in combination with labeled anti-CD133 antibodies. Estrogen, a known risk factor for lung cancer progression, stimulated a modest increase in the numbers of CSC. In contrast to control CD133-/ALDH- tumor cell subsets, CSC subpopulations grew as tumor spheres and maintained self-renewal capacity in vitro and exhibited a greater tumorigenic capability than non-CSC subsets in vivo, properties indicative of CSC. Furthermore, resistance of CSC-like cells to cisplatin (a standard chemotherapy for NSCLC treatment) was fully reversed by treatment with parthenolide (PTL), a naturally-occurring sesquiterpene lactone compound with strong antitumor activity in leukemia and prostate cancer while sparing normal cells. The antitumor effect of PTL appears due to its action as a potent inhibitor of nuclear factor-βB (NF-κB) which is markedly activated by chemotherapy. To target CSC and suppress tumor progression, we synthesized and tested novel analogs of PTL with improved antitumor properties and aqueous solubility. PTL analogs inhibit proliferation of H157 NSCLC cells using both bulk cell preparations and CSC-subpopulations, with effects significantly different from control at PCitation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 3491. doi:1538-7445.AM2012-3491
- 15 April 2011
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 71 (8_Suppleme) , 5000
Abstract 5000: Tolerogenic transcription regulator Foxp3 controls the expression of immunosuppressive cytokines in melanoma cells
Foxp3 is a critical transcription regulator that is found commonly expressed in a subset of immunosuppressive CD4+/CD25+ T cells characterized as regulatory T cells (Tregs) in the immune system. Foxp3 is a member of the forkhead/winged-helix family of transcriptional regulators exhibiting both, activation and repression of transcription. Foxp3 is critically important for the development and function of Tregs and the consequent definition of immune-tolerance. Ectopic Foxp3 expression has been shown to -phenotypically and functionally- convert T cells to Tregs. Recently, we have characterized the expression of Foxp3 in a variety of human and mouse cancerous cells, either in tissue or in cultured cell lines. Although of cardinal importance, the specific role and mechanisms involved in the Foxp3-mediated immunosuppressive activity remains elusive. Thus, we hypothesize that tumor-derived Foxp3 is controlling the transcriptional expression of immunosuppressive cytokines by tumor cells and inducing immunotolerance in the tumor microenvironment. We have tested this hypothesis by interrogating the well-characterized B16-C57BL/6 syngeneic mouse model of melanoma. Foxp3-expressing B16-F0 cells (B16-Foxp3+) where specifically and stably knockdown for Foxp3 expression by lentivirus-mediated shRNA (B16-Foxp3-). In order to determine the specific role and mechanisms of melanoma-derived Foxp3 in controlling the expression of immunosuppressive cytokines generated by melanoma cells, we have evaluated the differential cytokine expression profile between the B16Foxp3+ and the B16-Foxp3- cultured cells using Multiplex Bead Immunoassay, Immunoblotting Assay of Proteins and Semiquantitative RT-PCR. Our results demonstrated that the suppression of expression of Foxp3 in melanoma cells showed a significant downregulation of a selected group of immunosuppressive cytokines, in particular IL-4, IL-6, IL-10, IL-12, TNF-alpha and GM-CSF. In contrast, Foxp3 did not have an appreciable effect on the expression of IL-1, IL-2, IL-5, and IFN-gamma. Altogether, our data suggest the specific role of tumor-derived expression of FOXP3 in the control of the expression of tolerogenic/immunosuppressive cytokines secreted by melanoma cells to the tumor microenvironment. Furthermore, selective suppression of Foxp3 expression and/or activity in cancerous cells may help to develop better and more effective targeted immunotherapy as treatment for malignant melanoma. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 5000. doi:10.1158/1538-7445.AM2011-5000
- 15 April 2011
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 71 (8_Suppleme) , 5000
Abstract 5000: Tolerogenic transcription regulator Foxp3 controls the expression of immunosuppressive cytokines in melanoma cells
Foxp3 is a critical transcription regulator that is found commonly expressed in a subset of immunosuppressive CD4+/CD25+ T cells characterized as regulatory T cells (Tregs) in the immune system. Foxp3 is a member of the forkhead/winged-helix family of transcriptional regulators exhibiting both, activation and repression of transcription. Foxp3 is critically important for the development and function of Tregs and the consequent definition of immune-tolerance. Ectopic Foxp3 expression has been shown to -phenotypically and functionally- convert T cells to Tregs. Recently, we have characterized the expression of Foxp3 in a variety of human and mouse cancerous cells, either in tissue or in cultured cell lines. Although of cardinal importance, the specific role and mechanisms involved in the Foxp3-mediated immunosuppressive activity remains elusive. Thus, we hypothesize that tumor-derived Foxp3 is controlling the transcriptional expression of immunosuppressive cytokines by tumor cells and inducing immunotolerance in the tumor microenvironment. We have tested this hypothesis by interrogating the well-characterized B16-C57BL/6 syngeneic mouse model of melanoma. Foxp3-expressing B16-F0 cells (B16-Foxp3+) where specifically and stably knockdown for Foxp3 expression by lentivirus-mediated shRNA (B16-Foxp3-). In order to determine the specific role and mechanisms of melanoma-derived Foxp3 in controlling the expression of immunosuppressive cytokines generated by melanoma cells, we have evaluated the differential cytokine expression profile between the B16Foxp3+ and the B16-Foxp3- cultured cells using Multiplex Bead Immunoassay, Immunoblotting Assay of Proteins and Semiquantitative RT-PCR. Our results demonstrated that the suppression of expression of Foxp3 in melanoma cells showed a significant downregulation of a selected group of immunosuppressive cytokines, in particular IL-4, IL-6, IL-10, IL-12, TNF-alpha and GM-CSF. In contrast, Foxp3 did not have an appreciable effect on the expression of IL-1, IL-2, IL-5, and IFN-gamma. Altogether, our data suggest the specific role of tumor-derived expression of FOXP3 in the control of the expression of tolerogenic/immunosuppressive cytokines secreted by melanoma cells to the tumor microenvironment. Furthermore, selective suppression of Foxp3 expression and/or activity in cancerous cells may help to develop better and more effective targeted immunotherapy as treatment for malignant melanoma. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 5000. doi:10.1158/1538-7445.AM2011-5000
- 1 January 2011
- Published by Begell House Inc. Publishers in Critical Reviews™ in Oncogenesis
- Vol. 16 (3-4) , 227-238
Transcription Regulator Yin-Yang 1: From Silence to Cancer
Yin Yang (YY) 1 represents the epitome of what is considered to be a "Swiss army knife" transcription factor and regulator. YY1 is a ubiquitous and multifunctional zinc-finger transcription factor member of the Polycomb group protein family, a group of homeobox gene receptors that can act as activators or repressors of transcriptional activity. Furthermore, YY1 can act as a redox sensor, adaptor molecule, and chromatin structure and function regulator. YYl’s characteristic function as transcriptional activator and repressor relies on its C2H2 (x4) zinc-finger structural DNA-binding motifs tangled with 2 specific regulatory domains. This structural conformation will render the activity of YY1 susceptible to changes in cellular redox status. YY1 also has been shown to undergo chromatin remodeling via interactions with histone acetyl transferase and histone deacetylase complexes. Both groups modify histones, resulting in altered chromatin structure. Herein, we will discuss the multiple roles and mechanisms of YY1 in the regulation of gene expression, its genetic factor functions, epigenetic regulatory activity, and its role as a redox sensor in the context of malignant neoplastic diseases.
- 1 January 2011
- Published by Begell House Inc. Publishers in Critical Reviews™ in Oncogenesis
- Vol. 16 (3-4) , 227-238
Transcription Regulator Yin-Yang 1: From Silence to Cancer
Yin Yang (YY) 1 represents the epitome of what is considered to be a "Swiss army knife" transcription factor and regulator. YY1 is a ubiquitous and multifunctional zinc-finger transcription factor member of the Polycomb group protein family, a group of homeobox gene receptors that can act as activators or repressors of transcriptional activity. Furthermore, YY1 can act as a redox sensor, adaptor molecule, and chromatin structure and function regulator. YYl’s characteristic function as transcriptional activator and repressor relies on its C2H2 (x4) zinc-finger structural DNA-binding motifs tangled with 2 specific regulatory domains. This structural conformation will render the activity of YY1 susceptible to changes in cellular redox status. YY1 also has been shown to undergo chromatin remodeling via interactions with histone acetyl transferase and histone deacetylase complexes. Both groups modify histones, resulting in altered chromatin structure. Herein, we will discuss the multiple roles and mechanisms of YY1 in the regulation of gene expression, its genetic factor functions, epigenetic regulatory activity, and its role as a redox sensor in the context of malignant neoplastic diseases.
- Open Access
- 17 December 2010
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 107 (52) , E191
Reply to Klar: Key role of YY1 in neoangiogenesis
- 17 December 2010
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 107 (52) , E191
Open AccessReply to Klar: Key role of YY1 in neoangiogenesis
- Open Access
- 26 July 2010
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 107 (32) , 14484-14489
CXCR4/YY1 inhibition impairs VEGF network and angiogenesis during malignancy
Tumor growth requires neoangiogenesis. VEGF is the most potent proangiogenic factor. Dysregulation of hypoxia-inducible factor (HIF) or cytokine stimuli such as those involving the chemokine receptor 4/stromal-derived cell factor 1 (CXCR4/SDF-1) axis are the major cause of ectopic overexpression of VEGF in tumors. Although the CXCR4/SDF-1 pathway is well characterized, the transcription factors executing the effector function of this signaling are poorly understood. The multifunctional Yin Yang 1 (YY1) protein is highly expressed in different types of cancers and may regulate some cancer-related genes. The network involving CXCR4/YY1 and neoangiogenesis could play a major role in cancer progression. In this study we have shown that YY1 forms an active complex with HIF-1α at VEGF gene promoters and increases VEGF transcription and expression observed by RT-PCR, ELISA, and Western blot using two different antibodies against VEGFB. Long-term treatment with T22 peptide (a CXCR4/SDF-1 inhibitor) and YY1 silencing can reduce in vivo systemic neoangiogenesis ( P < 0.01 and P < 0.05 vs. control, respectively) during metastasis. Moreover, using an in vitro angiogenesis assay, we observed that YY1 silencing led to a 60% reduction in branches ( P < 0.01) and tube length ( P < 0.02) and a 75% reduction in tube area ( P < 0.001) compared with control cells. A similar reduction was observed using T22 peptide. We demonstrated that T22 peptide determines YY1 cytoplasmic accumulation by reducing its phosphorylation via down-regulation of AKT, identifying a crosstalk mechanism involving CXCR4/YY1. Thus, YY1 may represent a crucial molecular target for antiangiogenic therapy during cancer progression.
- 26 July 2010
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 107 (32) , 14484-14489
Open AccessCXCR4/YY1 inhibition impairs VEGF network and angiogenesis during malignancy
Tumor growth requires neoangiogenesis. VEGF is the most potent proangiogenic factor. Dysregulation of hypoxia-inducible factor (HIF) or cytokine stimuli such as those involving the chemokine receptor 4/stromal-derived cell factor 1 (CXCR4/SDF-1) axis are the major cause of ectopic overexpression of VEGF in tumors. Although the CXCR4/SDF-1 pathway is well characterized, the transcription factors executing the effector function of this signaling are poorly understood. The multifunctional Yin Yang 1 (YY1) protein is highly expressed in different types of cancers and may regulate some cancer-related genes. The network involving CXCR4/YY1 and neoangiogenesis could play a major role in cancer progression. In this study we have shown that YY1 forms an active complex with HIF-1α at VEGF gene promoters and increases VEGF transcription and expression observed by RT-PCR, ELISA, and Western blot using two different antibodies against VEGFB. Long-term treatment with T22 peptide (a CXCR4/SDF-1 inhibitor) and YY1 silencing can reduce in vivo systemic neoangiogenesis ( P < 0.01 and P < 0.05 vs. control, respectively) during metastasis. Moreover, using an in vitro angiogenesis assay, we observed that YY1 silencing led to a 60% reduction in branches ( P < 0.01) and tube length ( P < 0.02) and a 75% reduction in tube area ( P < 0.001) compared with control cells. A similar reduction was observed using T22 peptide. We demonstrated that T22 peptide determines YY1 cytoplasmic accumulation by reducing its phosphorylation via down-regulation of AKT, identifying a crosstalk mechanism involving CXCR4/YY1. Thus, YY1 may represent a crucial molecular target for antiangiogenic therapy during cancer progression.
- 8 April 2010
- Published by Springer Nature
- p. 283-290
Breaking Resistance: Role of Nitric Oxide in the Sensitization of Cancer Cells to Chemo- and immunotherapy
- 8 April 2010
- Published by Springer Nature
- p. 283-290
Breaking Resistance: Role of Nitric Oxide in the Sensitization of Cancer Cells to Chemo- and immunotherapy
- 11 November 2009
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 69 (22) , 8693-8699
Enhanced Antitumor Activity Induced by Adoptive T-Cell Transfer and Adjunctive Use of the Histone Deacetylase Inhibitor LAQ824
Tumors grow in the presence of antigen-specific T cells, suggesting the existence of intrinsic cancer cell escape mechanisms. We hypothesized that a histone deacetylase (HDAC) inhibitor could sensitize tumor cells to immunotherapy because this class of agents has been reported to increase tumor antigen expression and shift gene expression to a proapoptotic milieu in cancer cells. To test this question, we treated B16 murine melanoma with the combination of the HDAC inhibitor LAQ824 and the adoptive transfer of gp100 melanoma antigen-specific pmel-1 T cells. The combined therapy significantly improved antitumor activity through several mechanisms: (a) increase in MHC and tumor-associated antigen expression by tumor cells; (b) decrease in competing endogenous lymphocytes in recipient mice, resulting in a proliferative advantage for the adoptively transferred cells; and (c) improvement in the functional activity of the adoptively transferred lymphocytes. We confirmed the beneficial effects of this HDAC inhibitor as a sensitizer to immunotherapy in a different model of prophylactic prime-boost vaccination with the melanoma antigen tyrosinase-related protein 2, which also showed a significant improvement in antitumor activity against B16 melanoma. In conclusion, the HDAC inhibitor LAQ824 significantly enhances tumor immunotherapy through effects on target tumor cells as well as improving the antitumor activity of tumor antigen-specific lymphocytes. [Cancer Res 2009;69(22):8693–9]
- 11 November 2009
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 69 (22) , 8693-8699
Enhanced Antitumor Activity Induced by Adoptive T-Cell Transfer and Adjunctive Use of the Histone Deacetylase Inhibitor LAQ824
Tumors grow in the presence of antigen-specific T cells, suggesting the existence of intrinsic cancer cell escape mechanisms. We hypothesized that a histone deacetylase (HDAC) inhibitor could sensitize tumor cells to immunotherapy because this class of agents has been reported to increase tumor antigen expression and shift gene expression to a proapoptotic milieu in cancer cells. To test this question, we treated B16 murine melanoma with the combination of the HDAC inhibitor LAQ824 and the adoptive transfer of gp100 melanoma antigen-specific pmel-1 T cells. The combined therapy significantly improved antitumor activity through several mechanisms: (a) increase in MHC and tumor-associated antigen expression by tumor cells; (b) decrease in competing endogenous lymphocytes in recipient mice, resulting in a proliferative advantage for the adoptively transferred cells; and (c) improvement in the functional activity of the adoptively transferred lymphocytes. We confirmed the beneficial effects of this HDAC inhibitor as a sensitizer to immunotherapy in a different model of prophylactic prime-boost vaccination with the melanoma antigen tyrosinase-related protein 2, which also showed a significant improvement in antitumor activity against B16 melanoma. In conclusion, the HDAC inhibitor LAQ824 significantly enhances tumor immunotherapy through effects on target tumor cells as well as improving the antitumor activity of tumor antigen-specific lymphocytes. [Cancer Res 2009;69(22):8693–9]
- 20 September 2008
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 58 (5) , 699-708
Immunosensitization with a Bcl-2 small molecule inhibitor
Several tumor immunotherapy approaches result in a low percentage of durable responses in selected cancers. We hypothesized that the insensitivity of cancer cells to immunotherapy may be related to an anti-apoptotic cancer cell milieu, which could be pharmacologically reverted through the inhibition of antiapoptotic Bcl-2 family proteins in cancer cells. ABT-737, a small molecule inhibitor of the antiapoptotic proteins Bcl-2, Bcl-w and Bcl-xL, was tested for the ability to increase antitumor immune responses in two tumor immunotherapy animal models. The addition of systemic therapy with ABT-737 to the immunization of BALB/c mice with tumor antigen peptide-pulsed dendritic cells (DC) resulted in a significant delay in CT26 murine colon carcinoma tumor growth and improvement in survival. However, the addition of ABT-737 to either a vaccine strategy involving priming with TRP-2 melanoma antigen peptide-pulsed DC and boosting with recombinant Listeria monocytogenes expressing the same melanoma antigen, or the adoptive transfer of TCR transgenic cells, did not result in superior antitumor activity against B16 murine melanoma. In vitro studies failed to demonstrate increased cytotoxic lytic activity when testing the combination of ABT-737 with lymphokine activated killer (LAK) cells, or the death receptor agonists Fas, TRAIL-ligand or TNF-alpha against the CT26 and B16 cell lines. In conclusion, the Bcl-2 inhibitor ABT-737 sensitized cancer cells to the antitumor effect of antigen-specific immunotherapy in a vaccine model for the CT26 colon carcinoma in vivo but not in two immunotherapy strategies against B16 melanoma.
- 20 September 2008
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 58 (5) , 699-708
Immunosensitization with a Bcl-2 small molecule inhibitor
Several tumor immunotherapy approaches result in a low percentage of durable responses in selected cancers. We hypothesized that the insensitivity of cancer cells to immunotherapy may be related to an anti-apoptotic cancer cell milieu, which could be pharmacologically reverted through the inhibition of antiapoptotic Bcl-2 family proteins in cancer cells. ABT-737, a small molecule inhibitor of the antiapoptotic proteins Bcl-2, Bcl-w and Bcl-xL, was tested for the ability to increase antitumor immune responses in two tumor immunotherapy animal models. The addition of systemic therapy with ABT-737 to the immunization of BALB/c mice with tumor antigen peptide-pulsed dendritic cells (DC) resulted in a significant delay in CT26 murine colon carcinoma tumor growth and improvement in survival. However, the addition of ABT-737 to either a vaccine strategy involving priming with TRP-2 melanoma antigen peptide-pulsed DC and boosting with recombinant Listeria monocytogenes expressing the same melanoma antigen, or the adoptive transfer of TCR transgenic cells, did not result in superior antitumor activity against B16 murine melanoma. In vitro studies failed to demonstrate increased cytotoxic lytic activity when testing the combination of ABT-737 with lymphokine activated killer (LAK) cells, or the death receptor agonists Fas, TRAIL-ligand or TNF-alpha against the CT26 and B16 cell lines. In conclusion, the Bcl-2 inhibitor ABT-737 sensitized cancer cells to the antitumor effect of antigen-specific immunotherapy in a vaccine model for the CT26 colon carcinoma in vivo but not in two immunotherapy strategies against B16 melanoma.
- 1 September 2008
- Published by Elsevier in Nitric Oxide
- Vol. 19 (2) , 170-176
Regulation of apoptosis-related genes by nitric oxide in cancer
- 1 September 2008
- Published by Elsevier in Nitric Oxide
- Vol. 19 (2) , 170-176
Regulation of apoptosis-related genes by nitric oxide in cancer